2018 / 05

Next Paper
DOI: 10.24075/brsmu.2018.062

ORIGINAL RESEARCH

Evaluation of absorbed dose distribution in melanoma B16F10 during contrast enhanced radiotherapy with intratumoral administration of dose-enhancing agent

Lipengolts AA1,2,3, Vorobyeva ES2, Cherepanov AA1, Abakumov MA4,5, Abakumova TO6, Smirnova AV1,7, Finogenova YuA4, Grigorieva EYu1,3, Sheino IN2, Kulakov VN2
About authors

1 Blokhin National Medical Research Center of Oncology, Moscow, Russia

2 Burnasyan Federal Medical Biophysical Center, Moscow, Russia

3 Kurnakov Institute of General and Inorganic Chemistry, Moscow

4 Pirogov Russian National Research Medical University, Moscow, Russia

5 National University of Science and Technology "MISiS", Moscow

6 Skolkovo Institute of Science and Technology, Moscow

7 The Loginov Moscow Clinical Scientific Center, Moscow, Russia

Correspondence should be addressed: Alexey A. Lipengolts
Kashirskoe shosse 24, Moscow, 115478; ur.liam@stlognepil

About paper

Funding: the study was supported by the Russian Science Foundation (Project ID 18-13-00459).

Received: 2018-09-28 Accepted: 2018-10-20 Published online: 2018-12-01
|
Fig. 1. The CT scans of a mouse with melanoma B16F10 before (A) and after (B) the intratumoral injection of 50 μL of the Bi-DTPA solution containing bismuth at a concentration of 104.5 mg/mL
Fig. 2. The calibration curve showing the changes in radiopacity (ΔСT) detected on CT images produced by the micro-CT scanner IVIS Spectrum CT plotted against bismuth concentrations
Fig. 3. The kinetics of bismuth relative mass content in the tumor plotted against time elapsed after the injection
Fig. 4. The kinetics of DEA relative distribution volume in the tumor plotted against time elapsed after the injection
Fig. 5. The modified dose-volume histogram for B16F10 melanoma injected with DEA and subsequently exposed to X-rays for 28.5 minutes
Table. The main physical and chemical properties of the Bi-DTPA solution